Filing Analysis
InfuSystem Holdings, Inc. filed an 8-K to furnish an Investor Presentation dated August 4, 2026, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- An Investor Presentation was released on August 4, 2026 (Exhibit 99.1).
- The information provided in the presentation is not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. filed an 8-K to announce the release of its financial results for the second quarter of 2026. The filing serves as a formal notice that earnings data has been made public via a press release.
📋 Key Facts
- Reporting period: Second Quarter of 2026
- Report date: August 4, 2026
- The financial results were furnished in Exhibit 99.1 as a press release.
- Information under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. announced the upcoming release of its second quarter 2026 financial results and a corresponding investor conference call scheduled for August 4, 2026.
📋 Key Facts
- Q2 2026 financial results to be disclosed on Tuesday, August 4, 2026, before market open.
- Investor conference call scheduled for August 4, 2026, at 9:00 a.m. Eastern Time.
- The filing is made pursuant to Regulation FD (Item 7.01) to ensure simultaneous public disclosure.
InfuSystem Holdings, Inc. announced that its Board of Directors has authorized a new stock repurchase program for up to $20 million of its common stock. The program is set to commence on July 1, 2026, and will conclude on June 30, 2028.
📋 Key Facts
- The Board of Directors approved a stock repurchase program of up to $20 million.
- The repurchase period spans two years, from July 1, 2026, to June 30, 2028.
- The announcement was made via a press release furnished under Item 7.01 (Regulation FD).
- The filing was signed by CFO Barry Steele on May 18, 2026.
InfuSystem Holdings, Inc. announced the election of Beverly Huss as the new Chairman of the Board of Directors following its 2026 Annual Meeting of Stockholders.
📋 Key Facts
- Beverly Huss was elected Chairman of the Board on May 11, 2026.
- The election occurred during the first board meeting following the 2026 Annual Meeting of Stockholders.
- The company confirmed there are no related-party transactions or family relationships involving Ms. Huss requiring disclosure under Item 404(a).
InfuSystem Holdings, Inc. reported the results of its 2026 Annual Meeting of Stockholders, which included the approval of an amendment to the company's 2021 Equity Incentive Plan. Stockholders also elected seven directors and ratified the appointment of Grant Thornton LLP as the independent auditor for the 2026 fiscal year.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders was held on May 11, 2026.
- Stockholders approved the Third Amendment to the 2021 Equity Incentive Plan, increasing the maximum number of shares reserved for issuance to 7,000,000.
- Seven directors were elected to the Board: Kenneth D. Eichenbaum, Paul A. Gendron, Ronald Hundzinski, Beverly A. Huss, Carrie Lachance, Scott Shuda, and Dr. John J. Sviokla.
- Executive compensation was approved on a non-binding, advisory basis with 11,915,842 votes in favor.
- Grant Thornton LLP was ratified as the independent accounting firm for the fiscal year ending December 31, 2026, with overwhelming support (16,604,725 votes for).
InfuSystem Holdings, Inc. reported its financial results for the first quarter of 2026 on May 7, 2026. The announcement was made via a press release furnished under Item 2.02 of the Form 8-K.
📋 Key Facts
- The Company issued a press release reporting Q1 2026 financial results on May 7, 2026.
- The press release is furnished as Exhibit 99.1 to the filing.
- The filing was signed by Barry Steele, the Chief Financial Officer.
InfuSystem Holdings, Inc. announced it will release its first quarter 2026 financial results on May 7, 2026, before the market opens. The company will also host a conference call for investors at 9:00 a.m. Eastern Time on the same day.
📋 Key Facts
- Earnings release date set for Thursday, May 7, 2026.
- Conference call scheduled for May 7, 2026, at 9:00 a.m. ET.
- The filing covers the financial results for the first quarter of 2026.
- The announcement was made via a press release furnished as Exhibit 99.1.
InfuSystem Holdings, Inc. has dismissed Deloitte & Touche LLP and appointed Grant Thornton LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. The change followed a competitive selection process conducted by the Audit Committee.
📋 Key Facts
- Deloitte & Touche LLP was dismissed on March 13, 2026.
- Grant Thornton LLP was appointed as the new auditor for the 2026 fiscal year on the same date.
- Deloitte's audit reports for the fiscal years ended December 31, 2025, and 2024, contained no adverse opinions or qualifications.
- There were no disagreements with Deloitte on any matter of accounting principles, practices, or financial statement disclosure during the two most recent fiscal years.
- The company did not consult Grant Thornton on any accounting or auditing matters prior to their appointment.
InfuSystem Holdings, Inc. announced that its President and CEO, Carrie Lachance, and CFO, Barry Steele, will participate in the 38th Annual ROTH Conference on March 23, 2026.
📋 Key Facts
- The company will participate in the 38th Annual ROTH Conference on March 23, 2026.
- Key executives attending include CEO Carrie Lachance and CFO Barry Steele.
- The announcement was made via a press release dated March 16, 2026, furnished under Item 7.01.
InfuSystem Holdings, Inc. furnished an updated investor presentation dated February 27, 2026, under Regulation FD.
📋 Key Facts
- The filing was made on February 27, 2026, under Item 7.01 (Regulation FD Disclosure).
- The primary content is an Investor Presentation attached as Exhibit 99.1.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
- The report was signed by Barry Steele, the Chief Financial Officer.
InfuSystem Holdings, Inc. reported its financial results for the fourth quarter and full fiscal year 2025. The results were disclosed via a press release on February 24, 2026.
📋 Key Facts
- The filing reports financial results for the fourth quarter and fiscal year ended 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release is included as Exhibit 99.1.
- The report was signed by CFO Barry Steele on February 24, 2026.
InfuSystem Holdings, Inc. announced it will release preliminary financial results for the fourth quarter and fiscal year 2025 on February 24, 2026.
📋 Key Facts
- Preliminary Q4 and FY2025 financial results to be disclosed on February 24, 2026, before market open.
- Conference call for investors scheduled for February 24, 2026, at 9:00 a.m. ET.
InfuSystem Holdings announced that CMS has added two of its electronic infusion pumps used in Pain Management services to the list of qualifying products for separate payment under the NOPAIN Act. This regulatory development allows for enhanced reimbursement pathways for these specific products.
📋 Key Facts
- CMS (Centers for Medicare and Medicaid Services) updated product eligibility under the NOPAIN Act.
- Two electronic infusion pumps used in InfuSystem's Pain Management services are now qualifying products for separate payment.
- The announcement was made via a press release dated December 10, 2025.
InfuSystem Holdings, Inc. filed an 8-K to furnish an Investor Presentation dated November 13, 2025, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is a Regulation FD disclosure (Item 7.01).
- An Investor Presentation was released on November 13, 2025 (Exhibit 99.1).
- The information provided is not considered 'filed' for the purposes of Section 18 liability.
InfuSystem Holdings, Inc. announced that its President/CEO Carrie Lachance and CFO Barry Steele will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025.
📋 Key Facts
- Event: 16th Annual Craig-Hallum Alpha Select Conference
- Date of Event: Tuesday, November 18, 2025
- Participants: Carrie Lachance (President and CEO) and Barry Steele (CFO)
- Filing Date: November 10, 2025
InfuSystem Holdings, Inc. filed an 8-K to announce the release of its financial results for the third quarter of 2025.
📋 Key Facts
- The company issued a press release on November 4, 2025, reporting Q3 2025 financial results.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Financial results are furnished in Exhibit 99.1.
InfuSystem Holdings, Inc. announced the upcoming release of its third quarter 2025 financial results and a corresponding investor conference call scheduled for November 4, 2025.
📋 Key Facts
- Q3 2025 financial results to be disclosed on Tuesday, November 4, 2025, before market open.
- Investor conference call scheduled for November 4, 2025, at 9:00 a.m. Eastern Time.
- The filing is a Regulation FD disclosure regarding the timing of material non-public information release.
InfuSystem Holdings, Inc. filed an 8-K to furnish an Investor Presentation dated October 6, 2025, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is a Regulation FD Disclosure (Item 7.01).
- An Investor Presentation was released on October 6, 2025, as Exhibit 99.1.
- The information provided in the presentation is not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. announced that its CEO and CFO will participate in the upcoming 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025.
📋 Key Facts
- CEO Carrie Lachance and CFO Barry Steele to attend the conference.
- Conference date: Thursday, October 9, 2025.
- Event name: 4th Annual ROTH Healthcare Opportunities Conference.
InfuSystem Holdings, Inc. filed an 8-K to announce the release of its financial results for the second quarter of 2025.
📋 Key Facts
- The company issued a press release on August 5, 2025, reporting Q2 2025 financial results.
- Financial results are furnished as Exhibit 99.1 and are not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. has announced the upcoming release of its second quarter 2025 financial results and a corresponding investor conference call scheduled for August 5, 2025.
📋 Key Facts
- Q2 2025 financial results to be disclosed on Tuesday, August 5, 2025, before market open.
- Investor conference call scheduled for August 5, 2025, at 9:00 a.m. Eastern Time.
- The filing is made pursuant to Regulation FD (Fair Disclosure) requirements.
InfuSystem Holdings, Inc. entered into a Second Amendment to its Credit Agreement on July 15, 2025. The amendment primarily serves to extend the maturity date of the existing credit facility to July 15, 2030.
🚩 Red Flags
- None identified in this specific filing
📋 Key Facts
- Date of event: July 15, 2025
- Parties involved: InfuSystem Holdings, Inc. (and subsidiaries) and JPMorgan Chase Bank, N.A. as administrative agent
- Primary action: Extension of the maturity date for the Credit Agreement to July 15, 2030
- Original agreement date: February 5, 2021
InfuSystem Holdings, Inc. has entered into a Second Amended and Restated Employment Agreement with Carrie Lachance following her promotion from President and COO to President and CEO on May 19, 2025. The filing also notes the approval of Charter Amendments by stockholders during the 2025 Annual Meeting.
🚩 Red Flags
- None identified; the filing describes standard executive compensation adjustments following a leadership transition.
📋 Key Facts
- Carrie Lachance promoted to President and CEO effective May 19, 2025.
- New base salary set at $500,000 with an annual performance bonus of up to 100% of base salary.
- Grant of 200,000 performance-based vesting restricted stock units (PSUs) tied to volume-weighted adjusted price targets through 2028.
- Grant of 128,000 stock options vesting over four years.
- Severance provisions include 12 months of base salary for involuntary termination and 18 months in the event of a change in control.
- Stockholders approved Charter Amendments on May 15, 2025, regarding forum selection and officer liability limits.
InfuSystem Holdings, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on May 15, 2025. The meeting resulted in the election of all seven board nominees and approval of several key shareholder proposals, including an amendment to the 2021 Equity Incentive Plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- The 2025 Annual Meeting was held on May 15, 2025.
- Stockholders approved a Second Amendment to the 2021 Equity Incentive Plan, increasing the maximum number of shares reserved for issuance to 6,000,000 shares.
- Ronald Hundzinski was elected as Chairman of the Board; the role of Executive Chairman has been disbanded.
- All seven proposed board nominees were successfully elected.
- Shareholders approved a non-binding advisory vote on executive compensation (Say-on-Pay).
- Deloitte & Touche LLP was ratified as the independent accounting firm for fiscal year 2025.
InfuSystem Holdings, Inc. filed an 8-K to furnish an Investor Presentation dated May 9, 2025, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- An Investor Presentation was released on May 9, 2025 (Exhibit 99.1).
- The information provided is not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. filed an 8-K to announce the release of its financial results for the first quarter of 2025. The filing serves as a vehicle to furnish the press release containing these results via Exhibit 99.1.
📋 Key Facts
- Reporting date: May 8, 2025
- Subject matter: Q1 2025 financial results
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. announced it will release its first quarter 2025 financial results on May 8, 2025, accompanied by an investor conference call.
📋 Key Facts
- Q1 2025 financial results to be disclosed on Thursday, May 8, 2025, before market open.
- Investor conference call scheduled for May 8, 2025, at 9:00 a.m. Eastern Time.
- The filing is a Regulation FD disclosure regarding upcoming earnings announcement.
InfuSystem Holdings, Inc. announced the departure of CEO Richard A. DiIorio effective May 19, 2025. He will be succeeded by current President and COO Carrie Lachance, while Scott Shuda moves to Executive Chairman.
🚩 Red Flags
- Leadership transition in a micro-cap environment can lead to short-term strategic uncertainty.
📋 Key Facts
- CEO Richard A. DiIorio to step down on May 19, 2025 (Separation Date).
- Carrie Lachance appointed as new CEO effective May 19, 2025; she is currently the President and COO.
- Scott Shuda appointed Executive Chairman of the Board.
- The separation is not due to any disagreement with the Company or its operations/policies.
- DiIorio will continue to serve on the Board until his term expires on May 15, 2025.
InfuSystem Holdings, Inc. issued an 8-K to furnish its financial results for the fourth quarter and fiscal year ended 2024. The filing serves as a formal announcement of the company's recent earnings performance.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year 2024.
- Report date: March 4, 2025.
- The financial results were released via press release (Exhibit 99.1).
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. announced the upcoming release of its preliminary financial results for the fourth quarter and fiscal year 2024. The company plans to disclose these results on March 4, 2025, accompanied by an investor conference call.
📋 Key Facts
- Preliminary Q4 and FY2024 financial results will be disclosed on March 4, 2025, before market open.
- A conference call for investors is scheduled for March 4, 2025, at 9:00 a.m. ET.
- The filing was made under Item 7.01 (Regulation FD) and includes a press release as Exhibit 99.1.
InfuSystem Holdings, Inc. has filed an 8-K to furnish an Investor Presentation dated December 4, 2024, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- An Investor Presentation was released on December 4, 2024 (Exhibit 99.1).
- The information provided in the presentation is not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. announced that its top executive team (CEO, CFO, and President/COO) will present at the Sidoti Small Cap Virtual Investor Conference on December 4, 2024.
📋 Key Facts
- Richard DiIorio (CEO), Barry Steele (CFO), and Carrie Lachance (President and COO) are scheduled to present.
- The presentation will take place at the Sidoti Small Cap Virtual Investor Conference on December 4, 2024.
- The filing is a Regulation FD disclosure regarding upcoming investor relations activities.
InfuSystem Holdings, Inc. announced the expansion of its Board of Directors from seven to eight members with the election of Ron Hundzinski. Mr. Hundzinski will serve on the Board and as a member of the Audit Committee.
📋 Key Facts
- Board size expanded from 7 to 8 members effective November 12, 2024.
- Ron Hundzinski elected to fill the new vacancy; term expires in 2025 or until successor is qualified.
- Mr. Hundzinski will serve on the Audit Committee.
- Hundzinski has extensive CFO experience at public companies including BorgWarner, Inc., Tenneco Inc., and TI Fluid Systems.
InfuSystem Holdings, Inc. filed an 8-K to announce the release of its third quarter 2024 financial results. This is a routine earnings announcement filing.
📋 Key Facts
- The company issued a press release on November 7, 2024, reporting Q3 2024 financial results.
- Financial results are furnished as Exhibit 99.1 and are not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. announced its upcoming third quarter 2024 financial results release and investor conference call scheduled for November 7, 2024.
📋 Key Facts
- Q3 2024 financial results to be disclosed on Thursday, November 7, 2024, before market open.
- Investor conference call scheduled for November 7, 2024, at 9:00 a.m. Eastern Time.
- The filing is a Regulation FD disclosure regarding the timing of material non-public information release.
InfuSystem Holdings, Inc. announced that its top executive team will participate in the Lytham Partners Fall 2024 Conference on October 1, 2024.
📋 Key Facts
- CEO Richard DiIorio, President/COO Carrie Lachance, and CFO Barry Steele to attend the conference.
- Conference date: Tuesday, October 1, 2024.
- The filing is a Regulation FD disclosure regarding upcoming investor relations activity.
InfuSystem Holdings, Inc. filed an 8-K to furnish an Investor Presentation dated September 12, 2024, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is a Regulation FD disclosure (Item 7.01).
- An Investor Presentation was released on September 12, 2024 (Exhibit 99.1).
- The information furnished under Item 7.01 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
InfuSystem Holdings, Inc. announced an exclusive U.S. distribution agreement and a minority investment in ChemoMouthpiece, LLC, in partnership with its joint venture partner Sanara MedTech Inc.
📋 Key Facts
- Date of event: September 11, 2024
- Partnership involved: Joint venture partner Sanara MedTech Inc. ('Sanara')
- Counterparty: ChemoMouthpiece, LLC
- Nature of agreement: Exclusive United States distribution agreement and minority investment
- Filing Item: Regulation FD Disclosure (Item 7.01)
InfuSystem Holdings, Inc. announced that CEO Richard DiIorio and CFO Barry Steele will participate in the Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference on September 12, 2024.
📋 Key Facts
- CEO Richard DiIorio to attend conference.
- CFO Barry Steele to attend conference.
- Conference Date: Thursday, September 12, 2024.
- Event Name: Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference.
InfuSystem Holdings, Inc. filed an 8-K to furnish its second quarter 2024 financial results via a press release. The filing does not contain substantive news regarding corporate changes or material agreements.
📋 Key Facts
- The company issued a press release reporting financial results for the second quarter of 2024 on August 8, 2024.
- Results are furnished as Exhibit 99.1 and are not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. has entered into a three-year distribution agreement with Smith+Nephew for the company's negative pressure wound therapy system and related supplies.
📋 Key Facts
- Agreement duration: Three years.
- Counterparty: Smith+Nephew (a major medical technology player).
- Scope: Distribution of InfuSystem's negative pressure wound therapy system and supplies.
- Filing date: August 6, 2024.
InfuSystem Holdings, Inc. announced the upcoming release of its second quarter 2024 financial results and a corresponding investor conference call scheduled for August 8, 2024.
📋 Key Facts
- Q2 2024 financial results to be disclosed on Thursday, August 8, 2024, before market open.
- Investor conference call scheduled for August 8, 2024, at 9:00 a.m. Eastern Time.
- The filing is made pursuant to Regulation FD (Fair Disclosure) requirements.
InfuSystem Holdings, Inc. filed an 8-K to furnish an Investor Presentation dated June 12, 2024, pursuant to Regulation FD Disclosure.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- An Investor Presentation was released on June 12, 2024 (Exhibit 99.1).
- The information provided is not considered 'filed' for purposes of Section 18 liability.
InfuSystem Holdings, Inc. announced that its executive leadership team will present at the Sidoti's Small Cap Virtual Investor Conference on June 12, 2024.
📋 Key Facts
- CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance are scheduled to present.
- The presentation is part of Sidoti's Small Cap Virtual Investor Conference.
- Event date: June 12, 2024.
InfuSystem Holdings, Inc. announced that its Board of Directors has approved a new stock repurchase program. The company is authorized to buy back up to $20 million of its common stock.
📋 Key Facts
- Board approval granted for a stock repurchase program.
- Total authorization amount: $20 million.
- Program expiration date: June 30, 2026.
- The announcement was made via press release on May 20, 2024.
InfuSystem Holdings, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on May 16, 2024. The meeting included elections for the Board of Directors and advisory votes on executive compensation and auditor ratification.
📋 Key Facts
- Annual Meeting held on May 16, 2024.
- All seven Board nominees (Ralph Boyd, Richard DiIorio, Kenneth Eichenbaum, Paul Gendron, Beverly Huss, Carrie Lachance, and Scott Shuda) were elected to the Board.
- Stockholders approved executive compensation on a non-binding advisory basis (Say-on-Pay).
- Stockholders ratified the appointment of Deloitte & Touche LLP as the independent accounting firm for fiscal year ending December 31, 2024.
InfuSystem Holdings, Inc. filed an 8-K to furnish its financial results for the first quarter of 2024 via a press release.
📋 Key Facts
- The filing is related to Item 2.02: Results of Operations and Financial Condition.
- Financial results for Q1 2024 were reported on May 9, 2024.
- The earnings press release is attached as Exhibit 99.1.
InfuSystem Holdings, Inc. issued an 8-K to announce the upcoming release of its first quarter 2024 financial results and a corresponding investor conference call.
📋 Key Facts
- Q1 2024 financial results will be disclosed on Thursday, May 9, 2024, before market open.
- An investor conference call is scheduled for May 9, 2024, at 9:00 a.m. Eastern Time.
- The filing includes an exhibit (99.1) containing the press release regarding these dates.
InfuSystem Holdings, Inc. received a notice from NYSE American LLC stating it is non-compliant with timely filing requirements after failing to file its 2023 Annual Report on Form 10-K by the April 1, 2024 deadline. The delay is due to internal procedures involving expense classification errors and the adoption of ASC 842 lease accounting standards.
🚩 Red Flags
- Delisting notice due to failure to timely file annual reports.
- Potential financial restatement implied by the need to reclassify expenses between G&A and Cost of Sales.
- Internal control/accounting complexity regarding ASC 842 adoption.
📋 Key Facts
- Received notice from NYSE Regulation on April 2, 2024, regarding non-compliance with timely filing criteria (Section 1007).
- The company failed to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
- Delays are attributed to evaluating errors in classifying general and administrative expenses vs. cost of sales.
- Delays also stem from the adoption/application of ASC 842 (Leases).
- The company has an 'Initial Cure Period' of six months from April 1, 2024, to file the delinquent report.
InfuSystem Holdings, Inc. filed an 8-K to furnish its financial results for the fourth quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Reported financial results for Q4 and FY 2023 on March 14, 2024.
- The filing includes a press release (Exhibit 99.1) detailing the company's operational and financial performance.
- Information provided under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
InfuSystem Holdings announced a Cooperation Agreement involving the resignation of Director R. Rimmy Malhotra and Nicoya Capital LLC. The agreement includes significant separation payments and strict standstill provisions to resolve potential disputes.
🚩 Red Flags
- Significant cash outflow ($625,000) to settle a director/investor exit.
- Presence of 'standstill' and 'release' provisions often indicates prior or potential litigation/dispute with an activist investor (Nicoya Capital LLC).
- The requirement for the departing director to vote in conformity with Board recommendations is highly unusual and suggests a settlement to secure board control.
📋 Key Facts
- R. Rimmy Malhotra resigned from the Board effective March 8, 2024.
- The Company will pay a $500,000 one-time separation payment to Nicoya Capital LLC.
- Mr. Malhotra will receive $125,000 in compensation for surrendered stock options and remaining term compensation.
- Total 'Exit Consideration' equals $625,000.
- A 3-year standstill provision prohibits Mr. Malhotra and Nicoya from acquiring shares, making tender offers, or engaging in proxy solicitations without Board consent.
- The agreement includes mutual non-disparagement clauses for three years.
- Mr. Malhotra agreed to vote his shares in conformity with the Board's recommendations for a period of time.
InfuSystem Holdings, Inc. announced the upcoming release of its preliminary financial results for the fourth quarter and fiscal year 2023. The company plans to disclose these results on March 14, 2024, accompanied by an investor conference call.
📋 Key Facts
- Preliminary Q4 and FY2023 financial results scheduled for release on March 14, 2024, before market open.
- Investor conference call scheduled for March 14, 2024, at 9:00 a.m. ET.
- The disclosure is being made pursuant to Regulation FD.